Shuai Wang1, Yiying Jia2, Xiangyan Cao3, Sining Feng2, Li Na4, Hongxuan Dong5, Jian Gao5, Lixin Zhang6. 1. Department of Rehabilitation, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China; Department of Rehabilitation, Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, People's Republic of China. 2. Department of Rehabilitation, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China. 3. Kidney internal medicine, Tangdu Hospital of Air Force Military Medical University, Xi'an, Shaanxi 710032, People's Republic of China. 4. Department of Rehabilitation, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China; Department of Neurology, People's Hospital of Liaoning Province, Shenyang 116044, People's Republic of China. 5. Technology Department, Liaoning Qifu Stem Cell Biotechnology Co., Ltd., Shenyang 110136, People's Republic of China. 6. Department of Rehabilitation, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China. Electronic address: zhanglxs1974@163.com.
Abstract
AIMS: Spinal cord injury (SCI) is a major cause of long-term physical impairment. Currently, treatment for SCI is limited to supportive measures, which can lead to permanent disability, representing a serious social burden. The present study aimed to evaluate the inflammatory microenvironment effects of human umbilical cord mesenchymal stem cells (HUCMSCs)+ Ultrashort Wave (USW) therapy on SCI and reveal possible mechanisms. MAIN METHODS: Low-dose USW was treated one day after SCI, and HUCMSCs suspension was transferred to the lesion using a micro-syringe 7 days after SCI. The functional effects of HUCMSCs and USW, separately and combinedly, were measured, together with the infiltration of CD3+ cells, formation of A1 astrocytes and activation of NUR77/ NF-κB pathway. KEY FINDINGS: Our results showed that HUCMSCs+USW therapy improved motor function of SCI rat, together with decreased infiltration of CD3+ T cells, and decreased induction of microglia and A1 astrocytes. And also USW treatment played a very important role on decreasing the infiltration of CD3+ T cells and IBA-1+ cells. Reduced production of pro-inflammatory cytokines IL-1β and IL-6 was also observed in rats receiving HUCMSCs+USW therapy, medicated by NUR77/NF-κB pathway. SIGNIFICANCE: These findings indicated that HUCMSCs+USW therapy could attenuate inflammatory microenvironment through NUR77/NF-κB signaling pathway, which might contribute to its better outcome.
AIMS: Spinal cord injury (SCI) is a major cause of long-term physical impairment. Currently, treatment for SCI is limited to supportive measures, which can lead to permanent disability, representing a serious social burden. The present study aimed to evaluate the inflammatory microenvironment effects of human umbilical cord mesenchymal stem cells (HUCMSCs)+ Ultrashort Wave (USW) therapy on SCI and reveal possible mechanisms. MAIN METHODS: Low-dose USW was treated one day after SCI, and HUCMSCs suspension was transferred to the lesion using a micro-syringe 7 days after SCI. The functional effects of HUCMSCs and USW, separately and combinedly, were measured, together with the infiltration of CD3+ cells, formation of A1 astrocytes and activation of NUR77/ NF-κB pathway. KEY FINDINGS: Our results showed that HUCMSCs+USW therapy improved motor function of SCI rat, together with decreased infiltration of CD3+ T cells, and decreased induction of microglia and A1 astrocytes. And also USW treatment played a very important role on decreasing the infiltration of CD3+ T cells and IBA-1+ cells. Reduced production of pro-inflammatory cytokines IL-1β and IL-6 was also observed in rats receiving HUCMSCs+USW therapy, medicated by NUR77/NF-κB pathway. SIGNIFICANCE: These findings indicated that HUCMSCs+USW therapy could attenuate inflammatory microenvironment through NUR77/NF-κB signaling pathway, which might contribute to its better outcome.
Authors: Q Wu; M Qu; P Zhong; Y Zeng; J Wang; Q Zhang; Ting Wang; D Liu; L Yang; J Zhou; Tong Wang Journal: Bull Exp Biol Med Date: 2022-02-17 Impact factor: 0.737